Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLX01008
- Development stage
- Preclinical
- Lead developer
- Panacela Labs
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PLX01008 is a small molecule carbazole derivative developed by Panacela Labs, a subsidiary of Statera Biopharma. It belongs to a class of compounds known as xenomycins, which are characterized by their antimicrobial and antifungal properties. PLX01008 is primarily identified as a research-stage compound rather than a clinical-stage asset. While it has demonstrated activity against various pathogens in research settings, specific details regarding its molecular target or clinical development progress are limited, and it is not currently featured in the active clinical pipeline of Panacela Labs.
- Other names
- xenomycin
Beyond the preview
Go deeper on PLX01008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLX01008.